For important risk and disclaimer information, Click here.

Industry

Healthcare

Company Type

Pharmaceuticals

Size

$3 Million

Investment Type

Convertible Note

Overview

Gila is pioneering the most novel

therapeutic mechanism for the

treatment of obesity/cardiometabolic

disorders

PYY & GLP1 assets under development

World-class team

Strong collaborations with Eli Lilly & University of Pennsylvania

Raising $3 million to generate data and

bridge operations to $35m Series B VC

financing

Opportunity

Huge Market




Convertible Note Financing

  • Obesity >1Bn worldwide
  • Metabolic disease widespread

 

 

  • Metabolic disease widespread
  • Unprecedented use of lingual signaling à neural activation pathway

 

 

  • Novel/proprietary peptide development
  • Clinical research, quality, regulatory
  • Strategic rights
  • Potential equity investment

 

  • $3 Million
  • 34% US adults overweight; 42% obese
  • >1Bn worldwide with obesity
  • New drugs: Mounjaro™, Wegovy®
  • Improvement needed: efficacy / side effects

 

  • Breakthrough mechanism
  • Strong Ph I and pre-clinical data
  • Focus on PYY and GLP-1

 

  • New Chemical Entity (NCE)
  • Clinical trial operations
  • Strategic rights, license option

 

  • Data generation in support of $35m Series B venture capital financing
  • $2.7m currently invested of $5m target

Solution/Strategy

OBESITY AMPLIFIES MANY CHRONIC DISEASES, ADDING BILLIONS TO U.S. HEALTHCARE COST

2/3 of US population with Overweight

1/3 of US population with Obesity

NEW APPROVALS DRIVING SIGNIFICANT AWARENESS / MARKET GROWTH

 

Eli Lilly Mounjaro | est. $100Bn / year (15mg tirzepatide)

 

 

 

 

 

 

 

Novo Nordisk Wegovy® | (2.4mg semaglutide, 2.4x Ozempic)

Learn More About Gila Therapeutics
Thank you for your interest in Gila Therapeutics.Please fill out your information and we will contact you shortly with more information on this opportunity.

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

CONTACT US

Hi. We're not around right now. But you can send us an email and we'll get back to you, asap.

Thanks, Ken

Ken Margolis | Managing Partner Castle Placement, LLC
1460 Broadway Street, Rte 400
New York, New York 10036
(212) 418-1188 | C: (516) 712-7784
kmargolis@castleplacement.com

Sending